Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2016, Vol. 7 Issue (1) : 36-44     DOI: 10.14336/AD.2015.0709
Original Article |
Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis
Zhang Jing-Zhan, Xie Xiang*, Ma Yi-Tong*, Zheng Ying-Ying, Yang Yi-Ning, Li Xiao-Mei, Fu Zhen-Yan, Dai Chuan-Fang, Zhang Ming-Ming, Yin Guo-Ting, Liu Fen, Chen Bang-Dang, Gai Min-Tao
Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, China
Download: PDF(503 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks     Supporting Info
Guide   
Abstract  

Polymorphisms in the apolipoprotein C-III (APOC3) gene have been reported to be associated with coronary heart disease (CHD), but the data so far have been conflicting. To derive a more precise estimation of these associations, we performed a meta-analysis to investigate the three main polymorphisms (SstI, T-455C, C-482T) of APOC3 in all published studies. Databases including PubMed, Web of Science, Wanfang, SinoMed and CNKI were systematically searched. The association was assessed using odds ratios (ORs) with 95% confidence intervals (CIs). The statistical analysis was performed using Review Manager 5.3.3 and Stata 12.0. A total of 31 studies have been identified. The pooled odds ratio (OR) for the association between the APOC3 gene polymorphisms and CHD and its corresponding 95% confidence interval (95% CI) were evaluated by random or fixed effect models. A statistical association between APOC3 SstI polymorphism and CHD susceptibility was observed under an allelic contrast model (P= 0.003, OR = 1.14, 95% CI = 1.05-1.24), dominant genetic model (P= 0.01, OR = 1.14, 95% CI = 1.03-1.26), and recessive genetic model (P= 0.02, OR = 1.35, 95% CI = 1.06-1.71), respectively. A significant association between the APOC3 T-455C polymorphism and CHD was also detected under an allelic contrast (P < 0.0001, OR = 1.19, 95% CI = 1.10-1.29), dominant genetic model (P= 0.0003, OR = 1.24, 95% CI = 1.11-1.39) and recessive genetic model (P= 0.04, OR = 1.30, 95% CI = 1.01-1.67). No significant association between the APOC3 C-482T polymorphism and CHD was found under an allelic model (P= 0.94, OR = 1.00, 95% CI = 0.93-1.08), dominant genetic model (P= 0.20, OR = 1.07, 95% CI = 0.97-1.18) or recessive genetic model (P= 0.13, OR = 0.90, 95% CI = 0.79-1.03). This meta-analysis revealed that the APOC3 SstI and T-455C polymorphisms significantly increase CHD susceptibility. No significant association was observed between the APOC3 C-482T polymorphism and CHD susceptibility.

Keywords APOC3      Coronary heart disease      Polymorphism      Meta-analysis     
Corresponding Authors: Xie Xiang,Ma Yi-Tong   
About author:

These authors equally contribute this work

Issue Date: 01 February 2016
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Zhang Jing-Zhan
Xie Xiang
Ma Yi-Tong
Zheng Ying-Ying
Yang Yi-Ning
Li Xiao-Mei
Fu Zhen-Yan
Dai Chuan-Fang
Zhang Ming-Ming
Yin Guo-Ting
Liu Fen
Chen Bang-Dang
Gai Min-Tao
Cite this article:   
Zhang Jing-Zhan,Xie Xiang,Ma Yi-Tong, et al. Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis[J]. Aging and disease, 2016, 7(1): 36-44.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2015.0709     OR     http://www.aginganddisease.org/EN/Y2016/V7/I1/36
Study [Reference]YearEligible subjectsAllele frequency (case)MethodPopulationCriteriaGender (male), %Age (years)
casecontrolS2TCCaseControlCaseControl
Aalto-Setälä [12]198739610.115--PCR-RFLPFinnishCHD10050.838-6818-52
Bai [13]199590680.328--PCR-RFLPJapaneseCHD77.857.463±1258±12
Berkinbayev [14]a20141611120.242--PCRKazakhstan(Kazakh)MI10010046.4±1.940.7±2.1
Berkinbayev [14]b201480950.285--PCRKazakhstan(Uyghur)CHD10010047.3±0.9241.2±1.02
Bi [15]2005312317--0.452PCR-RFLPChinese(Han)CAD6760.360.2±13.358.9±14.3
Che [16]20127878--0.647PCR-RFLPChineseCAD57.752.645.3±4.744.3±7.6
Chen [17]2006310499-0.4770.455PCR-RFLPChinese(Han)CHD70.662.760.56±11.1458.87±9.11
Chhabra [18]20041581510.342--PCRIndiaCAD889253.25±10.2552.45±10.85
Dallongeville [19]2006442475--0.263PCRFrenchCHD10010035-6435-64
Dan [20]199543600.221--PCR-RFLPChineseCHDN/AN/A57.6-6.955.4-4.3
Ding [21]2012229254-0.548-PCRChinese(Han)ACS55.953.959.1±9.459.3±9.6
Han [22]2011275289--0.481PCR-RFLPChinese(Han)CHD56.456.459.2±9.861.6±10.7
Izar [23]20031121120.136--PCRBrazilCAD5859M<45, W<55N/A
Kee [24]19996147610.093--PCREuropeMI10010025-64N/A
Li [25]2006471040.274--PCR-RFLPChinese(Han)CAD, MI72.360.662.5±12.160.0±8.0
Liu [26]20043853730.116--PCR-RFLPCaucasianMI10010060±959±9
Liu [27]20054835020.3010.5340.449PCR-RFLPChinese(Han)CHD5963.154.2±6.358.2±6.2
Liu [28]20052674910.301--PCR-RFLPChinese(Han)CHD70.463.760.3±8.958.8±9.2
Martinelli [29]2007669244---PCRItalyCAD, MI81.37560.7±9.358.7±12.7
Muendlein [30]2008332225--0.297PCRCaucasianCAD79.554.762.5±10.361.5±10.2
Olivieri [31]2002549251-0.416-PCRNorthern ItalyCAD81.866.960.4±9.457.6±12.6
Ordovas [32]19912021450.125--PCR-RFLPNorthern ItalyCADN/AN/A47.2±8.849.6±6.9
Paulweber [33]19881061180.104--PCR-RFLPAustrianCAD, MI10010047.3±5.749.7±5.4
Rigoli [34]199562620.169--PCR-RFLPSouthern ItalyCHD69.467.758.2±7.157.6±7.7
Sediri [35]20113263610.1030.411-PCRTunisiaMI10010053.8±8.651.1±9.5
Tarek [36]20131561540.292--PCR-RFLPEgyptianCAD10010051.5±7.950.7±9.4
Tarek [37]20112001000.145--PCREgyptianMI676450.7±9.552.9±11.3
Tobin [38]2004547505-0.3550.255PCR-RFLPUKMI686261.9±9.258.6±10.7
Weng [39]200050500.16--PCRChinese(Han)CAD, MI767457±6.855±8.7
Wu [40]20001312290.233--PCRChineseCAD69.556.859.1±10.951±15.3
Yang [41]20088587--0.412PCR-RFLPChineseCHD54.152.952.79±7.1550.63±7.50
Yi [42]2006195181--0.541PCR-RFLPChinese (Han)CAD56.456.469.48±9.2158.63±14.79
Yu [43]2011286325-0.420.517TaqManChinese (Han)CHD74.852.956.30±11.5755.79±12.40
Table 1  Characteristics of studies reporting the distribution of three APOC3 polymorphisms (SstI,-455T/C,-482C/T) in CHD cases and controls
Figure 1.  Flow diagram of the study identification.
Figure 2.  Forest plot of the association between the APOC3 SstI polymorphism and CHD under the allelic contrast model (S2 vs. S1). The horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the study-specific weight. The diamond represents the pooled results of the OR and the 95% CI.
Figure 3.  Forest plot of the association between the APOC3 T-455C polymorphism and CHD under the allelic contrast model (C vs. T). The horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight. The diamond represents the pooled results of the OR and the 95% CI.
Figure 4.  Forest plot of the association between the APOC3 C-482T polymorphism and CHD under the allelic contrast model (T vs. C). The horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study-specific weight. The diamond represents the pooled results of the OR and the 95% CI.
Figure 5.  Funnel plot for the publication bias tests. Each point represents a separate study for the indicated association. The horizontal and vertical axiscorrespond to the OR and confidence limits (OR: odds ratio, SE: standard error). A: SstI polymorphism under the allelic contrast model (S2 vs. S1); B: T-455C polymorphism under the allelic contrast model (C vs. T); C: C-482T polymorphism under the allelic contrast model (T vs. C).
[1] Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL (1990). Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science, 249:790-793.
[2] Bi N, Yan SK, Liet al. (2005). Polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi, 33:116-121.
[3] Isaacs A, Willems SM, Bos D,et al. (2013). Risk scores of common genetic variants for lipid levels influence atherosclerosis and incidentcoronary heart disease. Arterioscler Thromb Vasc Biol, 33:2233-2239.
[4] Martinelli N, Trabetti E, Bassi A,et al. (2007). The -1131 T&gt;C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis, 191:409-417.
[5] Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T (1995). Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest, 96:2601-2605.
[6] Wells GA, Shea B, O’Connell D, Peterson J, Welch V (2011). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2011 October 20.
[7] Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Heterogeneity in meta-analyses of genome-wide association investigations. PLoS One, 2:e841.
[8] Berkey CS, Hoaglin DC, Mosteller F, Colditz GA (1995). A random-effects regression model for meta-analysis. Stat Med, 14:395-411.
[9] DerSimonian R, Kacker R (2007). Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials, 28:105-114.
[10] Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22:719-748.
[11] Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315:629-634.
[12] Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nikkilä E (1987). DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis, 66:145-52.
[13] Bai H, Saku K, Liu R, Imamura M, Arakawa K (1995). Association between coronary heart disease and the apolipoprotein A-I/C-III/A-IV complex in a Japanese population. Hum Genet, 95:102-104.
[14] Berkinbayev S, Rysuly M, Mussayev A, Blum K, Baitasova N, Mussagaliyeva A,et al. (2014). Apolipoprotein Gene Polymorphisms (APOB, APOC111, APOE) in the Development of Coronary Heart Disease in Ethnic Groups of Kazakhstan. J Genet Syndr Gene Ther, 5:216.
[15] Bi N, Yan SK, Li GP,et al. (2005). Polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene in patients with coronary artery disease. Zhonghua Xin Xue Guan Bing Za Zhi, 33:116-121.
[16] Che YL, Chou GC (2012). Polymorphsims in the apolipoprotein A5 gene and apolipoprotein C3 gene in patients with coronary artery disease. Labeled Immunoassays and Clinical Medicine, 19:371-372.
[17] Chen SY (2006). Genetic analysis of haplotypes in the apo1ipoprotein A1-C3 gene region: effects on coronary heart disease and type 2 diabetes mellitus. Fujian Medical University, 1-47
[18] Chhabra S, Narang R, Lakshmy R,et al. (2004). Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD. Mol Cell Biochem, 259:59-66.
[19] Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P, Helbecque N (2006). Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Int J Cardiol, 106:152-156.
[20] Dan QH, Huang YW, Peng ZP (1995). Polymorphsims in the APO A-I/C-III/A-IV gene and apolipoprotein C3 gene in patients with coronary artery disease. National Medical Journal of China, 75:584-586.
[21] Ding Y, Zhu MA, Wang ZX, Zhu J, Feng JB, Li DS (2012). Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome. J Biomed Biotechnol, 2012:509420.
[22] Han TL (2011). A5/C3 Gene cluser and the correlation to the patients with coronary artery disease in ShanDong coastal areas. Shandong University, 1-50
[23] Izar MC, Fonseca FA, Ihara SS,et al. (2003). Risk Factors, biochemical markers, and genetic polymorphisms in early coronary artery disease. Arq Bras Cardiol, 80:379-395.
[24] Kee F, Amouyel P, Fumeron F,et al. (1999). Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. Atherosclerosis, 145:187-195.
[25] Li XD, Sun ZH, Yang ZY,et al. (2006). APOAl/C3 gene cluster polymorphisms and risk of coronary artery disease. Chinese Journal of Gerontology, 26:745-747.
[26] Liu S, Song Y, Hu FB,et al. (2004). A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis, 177:119-126.
[27] Liu HK (2005). Study on the association of single nucleotide polymorphisms in apolipoprotein APOAl/C3/A4/A5 gene cluster with coronary heart disease and type II diabetes. Sichuan University, 1-116
[28] Liu HK, Li FX, Zhang SZ,et al. (2005). Association of Sst I Polymorphism in Apolipoprotein C3 Gene with Hypertriglyceridaemia in Coronary Atherosclerotic Heart Disease and Type II Diabetes Mellitus in Chinese Population. ACTA GENETICA SINICA, 32:11-18.
[29] Martinelli N, Trabetti E, Bassi A,et al. (2007). The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis, 191:409-417.
[30] Muendlein A, Saely CH, Marte T,et al. (2008). Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease. Atherosclerosis, 199:179-186.
[31] Olivieri O, Stranieri C, Bassi A,et al. (2002). ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res, 43:1450-1457.
[32] Ordovas JM, Civeira F, Genest J Jr,et al. (1991). Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis, 87:75-86.
[33] Paulweber B, Friedl W, Krempler F, Humphries SE, Sandhofer F (1988). Genetic variation in the apolipoprotein AI-CIII-AIV gene cluster and coronary heart disease. Atherosclerosis, 73:125-133.
[34] Rigoli L, Raimondo G, Di Benedetto A,et al. (1995). Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus. Acta Diabetol, 32:251-256.
[35] Sediri Y, Kallel A, Feki M,et al. (2011). Association of a DNA polymorphism of the apolipoprotein AI-CIII-AIV gene cluster with myocardial infarction in a Tunisian population. Eur J Intern Med, 22:407-411.
[36] Abd-El-Aziz TA, Mohamed RH, El-Shal AS (2013). Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease. J Cardiovasc Transl Res, 6:430-435.
[37] Abd El-Aziz TA, Mohamed RH, Hashem RM (2011). Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients. Mol Cell Biochem, 354:141-150.
[38] Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K, Cheng S, Lindpaintner K, Samani NJ (2004). Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J, 25:459-467.
[39] Weng GL, Han QQ, Chen HZ,et al. (2000). Relationship of Apolipoprotein AI and CⅢ Loci Gene Polymorphism and Coronary Artery Disease. Journal of Fujian Medical University, 34:96-99.
[40] Wu JH, Kao JT, Wen MS, Lo SK (2000). DNA polymorphisms at the apolipoprotein A1-CIII loci in Taiwanese: correlation of plasma APOCIII with triglyceride level and body mass index. J Formos Med Assoc, 99:367-374.
[41] Yang QR, Ma GS, Chen Z,et al. (2008). The relationship between polymorphism of Apolipoprotein C-III gene and premature coronary heart disease. Practical Journal of Cardic Cerebral Pneumal and Vascular Disease, 16:1-4.
[42] Yi SX (2006). A study on the genes single nucleotide polymorphism of apolipoprotein A5 and C3 in patients with coronary artery disease. Qingdao University, 1-52
[43] Yu J, Huang J, Liang Y,et al. (2011). Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China. Lipids Health Dis, 10:200.
[44] Song C, Chang Z, Magnusson PK, Ingelsson E, Pedersen NL (2014). Genetic factors may play a prominent role in the development of coronary heart disease dependent on important environmental factors. J Intern Med, 275(6):631-639.
[1] Manuel Scimeca, Federica Centofanti, Monica Celi, Elena Gasbarra, Giuseppe Novelli, Annalisa Botta, Umberto Tarantino. Vitamin D Receptor in Muscle Atrophy of Elderly Patients: A Key Element of Osteoporosis-Sarcopenia Connection[J]. Aging and disease, 2018, 9(6): 952-964.
[2] Zhen Jie, Lin Tong, Huang Xiaochen, Zhang Huiqiang, Dong Shengqi, Wu Yifan, Song Linlin, Xiao Rong, Yuan Linhong. Association of ApoE Genetic Polymorphism and Type 2 Diabetes with Cognition in Non-Demented Aging Chinese Adults: A Community Based Cross-Sectional Study[J]. Aging and disease, 2018, 9(3): 346-357.
[3] Shen Ting, You Yuyi, Joseph Chitra, Mirzaei Mehdi, Klistorner Alexander, Graham Stuart L., Gupta Vivek. BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders[J]. Aging and disease, 2018, 9(3): 523-536.
[4] Li Xin, Zhou Xuan, Liu Howe, Chen Nan, Liang Juping, Yang Xiaoyan, Zhao Guoyun, Song Yanping, Du Qing. Effects of Elastic Therapeutic Taping on Knee Osteoarthritis: A Systematic Review and Meta-analysis[J]. Aging and disease, 2018, 9(2): 296-308.
[5] Pasqualetti Giuseppe, Seghieri Marta, Santini Eleonora, Rossi Chiara, Vitolo Edoardo, Giannini Livia, Malatesta Maria Giovanna, Calsolaro Valeria, Monzani Fabio, Solini Anna. P2X7 Receptor and APOE Polymorphisms and Survival from Heart Failure: A Prospective Study in Frail Patients in a Geriatric Unit[J]. Aging and disease, 2017, 8(4): 434-441.
[6] Wang Jue, Cao Bin, Han Dong, Sun Miao, Feng Juan. Long Non-coding RNA H19 Induces Cerebral Ischemia Reperfusion Injury via Activation of Autophagy[J]. Aging and disease, 2017, 8(1): 71-84.
[7] Chuan-Fang Dai, Xiang Xie, Yi-Tong Ma, Yi-Ning Yang, Xiao-Mei Li, Zhen-Yan Fu, Fen Liu, Bang-Dang Chen, Min-Tao Gai. Relationship between CYP17A1 Genetic Polymorphism and Essential Hypertension in a Chinese Population[J]. A&D, 2015, 6(6): 486-498.
[8] Nora S. Vyas,Yohan Lee,Kwangmi Ahn,Andrew Ternouth,Daniel R. Stahl,Ammar Al-Chalabi,John F. Powell,Basant K. Puri. Association of a Serotonin Receptor 2A Gene Polymorphism with Visual Sustained Attention in Early-Onset Schizophrenia Patients and their Non-Psychotic Siblings[J]. Aging and Disease, 2012, 3(4): 291-300.
[9] Jinesh Kochar,J. Michael Gaziano,Luc Djoussé. Dietary Factors and the Risk of Coronary Heart Disease[J]. Aging and Disease, 2011, 2(2): 149-157.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd